QA: Tvardi Therapeutics Inc in us_pharma/2014

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001346830_2015_Tvardi_Therapeutics_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}
warning No LiabilitiesAndStockholdersEquity node found input.sec.calculation_linkbase.edgar_model_mapping {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('LiabilitiesCurrent', 'LiabilitiesConvertiblePreferredStockAndStockholdersEquity', 'DeferredRentCreditNoncurrent', 'TemporaryEquityCarryingAmountAttributableToParent', 'StockholdersEquity', 'AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'RestrictedCashAndInvestmentsNoncurrent', 'CashAndCashEquivalentsAtCarryingValue', 'IncomeTaxesReceivable', 'PrepaidExpenseCurrent', 'AccountsPayableAndAccruedLiabilitiesCurrent', 'DeferredRevenueCurrent', 'PreferredStockValue', 'CommonStockValue', 'AdditionalPaidInCapitalCommonStock', 'RetainedEarningsAccumulatedDeficit'))"}

Graph

Absolute values for 0001346830, Tvardi Therapeutics Inc

  xvar xval
0 AssetsCurrent 53,150,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 2,084,000
3 remainder_Assets 700,000
4 LiabilitiesCurrent 3,398,000
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 6,181,000
9 ResearchAndDevelopmentExpense 15,068,000
10 remainder_Expenses -201,000
11 remainder_Revenues 3,177,000
12 remainder_NetIncome 126,000
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 55,934,000
1 Liabilities 3,398,000
2 Expenses 21,048,000
3 Revenues 3,177,000
4 StockholdersEquity 52,536,000
5 NetIncome -17,745,000
6 ComprehensiveNetIncome -17,745,000
7 BaseVar 41,841,500
8 EconomicCapitalRatiobeforeLimitedLiability 3.26
9 EconomicCapitalRatio 3.86

Edgar->Model Mapping

Feature Distribution